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Type 1 pili mediate binding, invasion, and biofilm formation of uropathogenic Escherichia coli (UPEC) in the
host urothelium during urinary tract infection (UTI) via the adhesin FimH. In this study, we characterized the
molecular basis of functional differences between FimH of the UPEC isolate UTI89 and the Klebsiella pneu-
moniae cystitis isolate TOP52. Type 1 pili characteristically mediate mannose-sensitive hemagglutination of
guinea pig erythrocytes. Although the adhesin domain of K. pneumoniae TOP52 FimH (FimH52) is highly
homologous to that of E. coli, with an identical mannose binding pocket and surrounding hydrophobic ridge,
it lacks the ability to agglutinate guinea pig erythrocytes. In addition, FimH-dependent biofilm formation in K.
pneumoniae is inhibited by heptyl mannose, but not methyl mannose, suggesting the need for contacts outside
of the mannose binding pocket. The binding specificity differences observed for FimH52 resulted in significant
functional differences seen in the pathogenesis of K. pneumoniae UTI compared to E. coli UTI. Infections in a
murine model of UTI demonstrated that although the K. pneumoniae strain TOP52 required FimH52 for
invasion and IBC formation in the bladder, FimH52 was not essential for early colonization. This work reveals
that a limited amount of sequence variation between the FimH of E. coli and K. pneumoniae results in
significant differences in function and ability to colonize the urinary tract.
Bacterial adherence to host mucosal surfaces is often an
important first step in the infection process. This is especially
true in the case of urinary tract infections (UTIs) (59). It is
estimated that half of all women will experience at least one
UTI in their lifetime (49), the vast majority of which are caused
by uropathogenic Escherichia coli (UPEC) and other Entero-
bacteriaceae (48). An essential step in UPEC infection of the
bladder is adherence to the host urothelial surface via type 1
pili (2, 27, 29). Type 1 pili are assembled via the chaperone/
usher pathway (3, 30, 53). They are adhesive hair-like fibers
consisting of cylindrical pilus rods composed of FimA pilin
subunits and small-tip fibrillae composed of FimF, FimG, and
the adhesin FimH (6, 31). The FimH adhesin recognizes man-
nosylated uroplakins and -1 and -3 integrin receptors on the
luminal surface of bladder urothelial cells (17, 29, 63). Binding
of UPEC to host cells induces a cascade of signaling events
that ultimately leads to bacterial internalization and the for-
mation of biofilm-like intracellular bacterial communities
(IBCs) (1, 17, 22, 32, 39, 43, 51). IBC formation is also depen-
dent on type 1 pili (62). Ultimately bacteria disperse from this
intracellular niche and progress to infect other urothelial cells.
Type 1 piliated bacteria have historically been characterized
by their ability to agglutinate guinea pig red blood cells (RBCs)
in a mannose-sensitive manner (14, 15, 52). This mannose-
sensitive hemagglutination (MSHA) phenotype of E. coli ex-
pressing type 1 pili requires the FimH adhesin. FimH consists
of two domains: an amino-terminal adhesin domain (AD; re-
ceptor binding domain) and a carboxy-terminal pilin domain
(PD) (8, 29, 31). FimH recognizes mannosylated glycoproteins,
including those present on the host urothelium through its AD.
FimH-mediated adhesion can be inhibited by D-mannose or
oligosaccharides containing terminal mannose residues (5, 19–
21). Additionally, it has been demonstrated that the FimH AD
binds more tightly to -D-mannosides with longer alkyl chains.
Heptyl mannose was found to have the highest affinity for
FimH (5). In animal models, neutralization of the adhesin by
FimH-specific antibodies protects from UPEC cystitis (35, 36).
X-ray crystal structures of FimH reveal a highly conserved
mannose binding pocket at the tip of the FimH AD sur-
rounded by a distal hydrophobic ridge (8, 29). Minor sequence
differences in E. coli FimH, many of which are not located in close
proximity to the mannose binding pocket, have been found to
correlate with differential binding phenotypes (54–56).
Klebsiella pneumoniae is the second leading cause of gram-
negative UTI but is a much less prevalent etiologic agent than
UPEC. K. pneumoniae genes encode numerous chaperone/
usher pili, including type 1 pili and type 3 pili (23). While type
1 pili have historically been defined by their MSHA phenotype,
type 3 pili display a mannose-resistant hemagglutination
(MRHA) with tannin-treated RBCs (47). Type 1 pili of K.
pneumoniae are highly homologous to those of UPEC (23) and
have been previously implicated in UTI pathogenesis (18, 40).
The fim operon of K. pneumoniae, encoding type 1 pili, con-
tains a terminal fimK gene, not present in UPEC, which plays
a role in suppressing the expression of type 1 pili (50). K.
pneumoniae binds, invades, and forms IBCs within host urothe-
lial cells, albeit less efficiently than UPEC in the murine cystitis
model. Similar to UPEC, K. pneumoniae also expresses type 1
pili within these IBCs (50). In this study, we discovered that
type 1-piliated K. pneumoniae cells are unable to mediate hem-
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agglutination of guinea pig erythrocytes despite the presence
of wild-type FimH containing an identical mannose binding
pocket to E. coli FimH. We analyzed functional and structural
differences in FimH of the K. pneumoniae strain TOP52 and
the effects of these differences on UTI pathogenesis.
MATERIALS AND METHODS
Bacterial strains and culture conditions. A complete list of bacterial strains
and plasmids used in this study can be found in Table 1. The clinical strains used
include UTI89, a UPEC cystitis isolate (43), and TOP52 1721 (abbreviated
TOP52 in this article), a K. pneumoniae cystitis isolate (50). Bacteria were
cultured at 37°C in Luria-Bertani (LB) broth containing, as appropriate, 20
g/ml chloramphenicol and 0.4% arabinose as indicated.
K. pneumoniae TOP52 and E. coli UTI89 mutant construction and comple-
mentation. A targeted deletion of fimH in the K. pneumoniae isolate TOP52 was
constructed with the pKOV vector as described previously (37). Flanking se-
quences of approximately 1,000 bp on each side of the targeted gene were
amplified with the indicated primers (Table 2) and cloned into pKOV. Potential
knockouts were screened by PCR, and the knockout region was sequenced.
Growth curves were performed for mutant strains and showed no differences in
growth compared to the wild type.
UTI89 fimH was constructed using the red recombinase method as previ-
ously described (10, 44), with pKD4 as a template and the primers indicated
(Table 2) followed by expression of the FLP recombinase to eliminate the
kanamycin cassette. PCR using flanking primers was used to confirm the dele-
tion.
For complementation studies, the ADs and PDs of both UTI89 fimH and
TOP52 fimH were amplified using the primers indicated (Table 2). Subscripts 89
and 52 were used to indicate a given domain was from UTI89 or TOP52,
respectively. Single ADs and PDs were added together as templates in a PCR to
create a full-length fimH gene that was subsequently cloned into the arabinose-
inducible pBAD33 vector (abbreviated pBAD). The four permutations of the
ADs and PDs yielded fimH complementation vectors pAD89PD89 (pfimH89),
pAD89PD52, pAD52PD89, and pAD52PD52 (pfimH52). All constructs were veri-
fied and sequenced using pBAD plasmid primers.
HAs. Hemagglutination assays (HAs) were performed with guinea pig RBCs
(optical density at 640 nm [OD640] of 2.0; Colorado Serum Company) as previ-
ously described using serial dilutions in microtiter plates with and without the
addition of 100 mM methyl -D-mannopyranoside (28).
Biofilm assays. Bacteria were grown in LB broth in wells of microtiter plates
in the presence of 0.01% arabinose and either no mannose, 1 mM methyl
mannose, 100 mM methyl mannose, or 1 mM heptyl mannose. After 48 h of
growth at room temperature, wells were rinsed and then stained with crystal
violet, and biofilms were quantified as previously described (46).
Modeling of K. pneumoniae FimH. K. pneumoniae TOP52 FimH was modeled
onto the X-ray crystal structure of E. coli FimH from the J96 isolate FimC-H
complex structure (PDB identification 1KLF) (29) using the protein structure
threading program Phyre (4). The resulting model was compared to the J96
TABLE 1. Bacterial strains and plasmids used in this study
Strain or plasmid Description Reference
Strains
UTI89 UPEC cystitis isolate 43
UTI89 fimH Knockout of fimH in UTI89 This study
TOP52 1721 K. pneumoniae cystitis isolate 50
TOP52 fimH Knockout of fimH in TOP52 1721 This study
TOP52 fimK Knockout of fimK in TOP52 1721 50
Plasmids
pBAD33 Empty expression vector; Para
Cmr
24





fimHUTI89 expression vector; Para
Cmr
This study










fimHTOP52 expression vector; Para
Cmr
This study
TABLE 2. Primer sequences
Name Use Sequence
NotIFimHF1 Amplify 1-kb K. pneumoniae fimH 5 flanking region 5-CGGTAACGCGGCCGCGGCGAATCGAAGGATTTTACT-3
BamHIFimHR2 Amplify 1-kb K. pneumoniae fimH 5 flanking region 5-AACGGATCCAAAGGACCAGGCGTTCATC-3
BamHIFimHF3 Amplify 1-kb K. pneumoniae fimH 3 flanking region 5-AACGGATCCACGCGATCTTCACCAATACC-3
SalIFimHR4 Amplify 1-kb K. pneumoniae fimH 3 flanking region 5-AACGTCGACGTCTGGGGGTGAAGTACCTG-3
FimHCheckF1 Check TOP52 fimH 5-GGACAGCACCGGCTATTACA-3
FimHCheckR2 Check TOP52 fimH 5-GGGATCGTCAGGGAGATACA-3
UTI89fimH KO F Knock out fimH in E. coli UTI89 5-ATGAAACGAGTTATTACCCTGTTTGCTGTACTGCTGAT
GGGCTGGTCGGTAGTGTAGGCTGGAGCTGCTTC-3
UTI89fimH KO R Knock out fimH in E. coli UTI89 5-TTATTGATAAACAAAAGTCACGCCAATAATCGATTGCA
CATTCCCTGCAGTCATATGAATATCCTCCTTAG-3
UTI89fimHcheckF Check UTI89 fimH 5-CAATCAGCGCACTTCCCGTTACAGG-3
UTI89fimHcheckR Check UTI89 fimH 5-CTCGAATTATAAACAACCCGCGGCG-3
2KlebphaseF Amplify fimS region for phase assay 5-GGGACAGATACGCGTTTGAT-3
2KlebphaseR Amplify fimS region for phase assay 5-GGGACAGATACGCGTTTGAT-3
ADecoliF Amplify E. coli fimH adhesin domain 5-AATTCCATGGGATGAAACGAGTTATTACCCTGTTTGCT
G-3
ADecoliR Amplify E. coli fimH adhesin domain 5-TCGCAGCCGCCAGTGGGCACCACCAC-3
PDecoliF Amplify E. coli fimH pilin domain 5-GTGGTGGTGCCCACTGGCGGCTGCGA-3
PDecoliR Amplify E. coli fimH pilin domain 5-AATTGGTACCATTGATAAACAAAAGTCACGCCAATAAT
CG-3
ADklebF Amplify K. pneumoniae fimH adhesin domain 5-AATTCCATGGGATGATGAAAAAAATAATCCCCCTGTTC
ACC-3
ADklebR Amplify K. pneumoniae fimH adhesin domain 5-TCGCAGCCGCCGGTGGGGACCACCAC-3
PDklebF Amplify K. pneumoniae fimH pilin domain 5-GTGGTGGTCCCCACCGGCGGCTGCGA-3
PDklebR Amplify K. pneumoniae fimH pilin domain 5-AATTGGTACCCATTGATAGACAAAGGTGATGCCGAT
G-3
pBADF Check pBAD33 clones 5-TATCGCAACTCTCTACTGTTTCTCCA-3
pBADR Check pBAD33 clones 5-CTGTATCAGGCTGAAAATCTTCTCTCA-3
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structure and UTI89 amino acid sequence. (A structure for UTI89 FimH has not
been solved to date, and J96 FimH differs by only 4 amino acids [aa] from UTI89
FimH.) Figures were rendered in the molecular modeling program Pymol (11).
Mouse infections. Bacterial strains were used to inoculate 8-week-old female
C3H/HeN mice (National Cancer Institute) by transurethral catheterization as
previously described (42). Twenty-five-milliliter static cultures were inoculated
from freezer stocks and grown at 37°C for 18 h and then subcultured 1:250 into
25 ml fresh medium. These cultures were then grown statically at 37°C for 18 h
and centrifuged for 5 min at 5,800 rpm, and the resultant pellet was resuspended
in phosphate-buffered saline (PBS) and diluted to approximately 2  108 CFU/
ml. Fifty microliters of this suspension was used to infect each mouse with an
inoculum of 1  107 to 2  107 CFU. All studies were approved by the Animal
Studies Committee at Washington University School of Medicine.
Organ titers, gentamicin protection assays, and IBC enumeration. To quantify
bacteria present in mouse organs, bladders and kidneys were aseptically har-
vested at the indicated times postinfection, homogenized in PBS, serially diluted,
and plated onto LB agar plates. Luminal and intracellular bacteria were quan-
tified using an ex vivo gentamicin protection assay as previously described (33).
For ex vivo enumeration of IBCs, infected bladders were harvested at 1 h
postinfection, bisected, splayed, washed with PBS, fixed with 3% paraformalde-
hyde for 1 h at room temperature and lacZ stained as previously described (33).
IBCs were visualized and counted using an Olympus SZX12 dissecting micro-
scope (Olympus America).
fim operon phase assay. To determine the orientation of the type 1 pilus
phase-variable promoter switch (fimS) in UTI89 fimH, a phase assay was
performed as previously described (58). Briefly, PCR primers were used to
amplify a 589-bp DNA region including fimS. The PCR product was then di-
gested with the restriction endonuclease HinfI (New England Biolabs) and was
separated on a 2.5% agarose gel. A phase-on switch results in products of 489
and 70 bp and a phase-off switch results in products of 359 and 200 bp.
Immunoelectron microscopy. Bacteria were prepared as described above for
mouse infection, fixed with 1% paraformaldehyde for 10 min, and absorbed onto
Formvar/carbon-coated copper grids for 2 min. Grids were washed two times
with PBS, blocked with 1% fetal bovine serum for 5 min, and incubated with
rabbit anti-FimH antibody (1:100) for 30 min at room temperature. The rabbit
anti-FimH antibody was raised against the FimH adhesin domain (positions 1 to
159, T2) of E. coli J96 (26) (SigmaGenesis). Grids were subsequently washed two
times with PBS, blocked with 1% fetal bovine serum for 5 min, and incubated
with 18-nm colloidal gold particle-conjugated anti-rabbit immunoglobulin G
(Jackson ImmunoResearch Laboratories) for 30 min at room temperature. Fol-
lowing two PBS washes, grids were rinsed in distilled water and stained with 1%
aqueous uranyl acetate (Ted Pella, Inc.) for 1 min. Excess liquid was gently
wicked off, and grids were air dried. Samples were viewed on a JEOL 1200EX
transmission electron microscope (JEOL USA) at 80 kV accelerating voltage.
Statistical analysis. Continuous variables were compared using the Mann-
Whitney U test since these variables were not normally distributed. All tests were
two-tailed, and a P value of 0.05 was considered significant. Analyses were
performed using GraphPad Prism (version 4.03) and SAS (version 9.0).
Nucleotide sequence accession number. The TOP52 fimH nucleotide sequence
has been deposited in the GenBank database under accession no. EU327536.
RESULTS
Type 1-piliated K. pneumoniae TOP52 is hemagglutination
negative. In contrast to UPEC, statically passaged K. pneu-
moniae TOP52 produced no detectable hemagglutination of
guinea pig RBCs despite expression of type 1 pili (Table 3).
The MSHA titer of the UPEC strain UTI89 was 1:512. Dele-
tion of fimH abolished the ability of UTI89 fimH to produce
MSHA. UTI89 fimH produced a low MRHA titer of 1:4,
unlike UTI89. Wild-type K. pneumoniae TOP52 did not agglu-
tinate guinea pig erythrocytes. Deletion of fimH to create
TOP52 fimH was also negative for hemagglutination. Re-
cently, we discovered that deletion of fimK, a gene unique to
Klebsiella fim gene clusters, resulted in a hyper-type 1-piliated
phenotype (50). The hyperpiliated TOP52 fimK was also
hemagglutination negative. The fimX recombinase has been
shown to have fimB-like properties (7, 25), and its overexpres-
sion results in increased expression of type 1 pili in both E. coli
(25) and K. pneumoniae (50). The hyperpiliated TOP52/pfimX
was also hemagglutination negative. Thus, type 1-piliated K.
pneumoniae TOP52 is unable to mediate MSHA.
FimH52 and FimH89 are highly similar in amino acid se-
quence and predicted structure. To further investigate the
functional differences of K. pneumoniae TOP52 type 1 pili, we
sequenced fimH52 (GenBank accession no. EU327536) and
compared it to other known K. pneumoniae FimH sequences
and the sequence of E. coli UTI89 FimH (FimH89). The
FimH52 amino acid sequence shares 100% identity with the
FimH adhesin domain of K. pneumoniae strain IA565 (23),
99.6% amino acid identity with the FimH of K. pneumoniae
ATCC 700721 strain (41), and 85.3% amino acid identity with
K. pneumoniae strain IA551 (16). FimH52 has 86.4% amino
acid identity to FimH of E. coli UTI89 (FimH89) (Fig. 1A) and
maintains the general bidomain composition of E. coli FimH
with an amino-terminal adhesin domain (amino acids [aa] 1 to
157) and a carboxy-terminal pilin domain (aa 161 to 279)
separated by a short linker region.
We threadedK. pneumoniae FimH onto the X-ray crystal struc-
ture of FimH from the complex structure of FimC-H from the J96
E. coli isolate (29). We then overlaid J96 FimH and TOP52 FimH
and compared the positions and identities of amino acid differ-
ences in FimH89 and FimH52 (Fig. 1B). This comparison assumes
that residues conserved between J96 FimH and UTI89 FimH
have the same conformation as shown in the three-dimensional
J96 FimH structure. There are only four amino acid differences
between FimH of these two strains. Seventeen AD amino acid
differences and 21 PD amino acid differences exist between
FimH89 and FimH52. Interestingly, FimH52 displays full conser-
vation of the residues known to interact with mannose in the
mannose binding pocket (orange) and those that form the sur-
rounding hydrophobic ridge (green in Fig. 1). Residue differences
exist in areas adjacent to the receptor binding site and in other
more distal parts of the molecule, which may together alter the
molecular details of the interaction with mannose. Two differ-
ences in FimH52 primary sequence exist in residues adjacent to
known mannose-binding residues (His132 and Ser141, changed
from Arg and Asp, respectively, in FimH89). The threaded model
FimH52 suggests that these residues would lie 	8.5 Å away from
the bound mannose moiety. Arg132 and Asp141 form a salt
bridge in E. coli FimH that helps stabilize the structure of the FG
TABLE 3. FimH52-specific inability of K. pneumoniae TOP52 to
agglutinate guinea pig RBCs
Strain







UTI89 fimH 2 2
TOP52 0 0
TOP52 fimH 0 0
TOP52 fimK 0 0
TOP52/pBAD 0 0
TOP52/pfimX 0 0
TOP52 fimH/pBAD 0 0
TOP52 fimH/pfimH52 0 0
TOP52 fimH/pfimH89 4 0
a HA titer data are representative of three independent experiments.
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loop that contains mannose binding residues Gln133, Asn135,
and Asp140 and forms part of the hydrophobic ridge. Arg132
NH1 also makes two hydrogen bonds to Gln59 OE1 and Glu89
OE1. In FimH52, His132 is only able to make a single hydrogen
bond with Glu89 OE2. Differences in these and other residues
may help explain the inability of K. pneumoniae TOP52 to agglu-
tinate guinea pig RBCs.
The inability of K. pneumoniae TOP52 to agglutinate guinea
pig RBCs is specific to the adhesin domain of FimH52. Al-
though all residues involved in direct interactions with the man-
nose moiety and all those in the surrounding hydrophobic ridge
are identical between FimH52 and FimH89, nearly 14% of amino
acids differ between the two proteins. We hypothesized that if this
variation in FimH sequence accounts for the inability to aggluti-
nate guinea pig erythrocytes, then complementation of TOP52
fimH with fimH cloned from E. coli UTI89 (fimH89), should
restore the MSHA phenotype. Thus, TOP52 fimH was comple-
mented with the fimH gene of K. pneumoniae TOP52 (fimH52) or
fimH89 on inducible plasmids. While the TOP52 fimH/pBAD
vector control and TOP52 fimH/pfimH52 were hemagglutina-
tion negative, TOP52 fimH/pfimH89 had an MSHA titer of 1:16
(Table 3). Thus, FimH89 is able to participate in type 1 pilus
biogenesis with the Fim proteins of K. pneumoniae TOP52 and
confers a gain of MSHA function.
To test the expression of exogenous fimH in the UTI89
fimH background, phase assays were conducted analyzing the
phase-variable promoter switch of type 1 pili (Fig. 2). The fim
operon of wild-type E. coli UTI89 was primarily phase on after
static growth; however, loss of fimH in UTI89 fimH and the
UTI89 fimH/pBAD vector control resulted in bacterial pop-
ulations that were primarily in the phase-off orientation.
Complementation with either pfimH89 or pfimH52 did not re-
sult in a robust off-to-on switch as the populations remained
primarily phase off with similarly low levels of piliated bacteria.
However, enough phase-on bacteria were present to detect an
MSHA titer with pfimH89 complementation (Table 3).
FimH52 and FimH89 function was investigated further by
constructing FimH chimeras. We used the chimeras to com-
plement fimH-knockout strains and then examined the final
pilus assembly on each strain by immunoelectron microscopy.
The ADs and PDs of each strain were amplified and expressed
in different combinations on the arabinose-inducible pBAD33
vector. This resulted in four different fimH construct-express-
ing plasmids: pAD89PD89 (pfimH89), pAD89PD52, pAD52PD89,
and pAD52PD52 (pfimH52).
The incorporation of pfimH89, pAD89PD52, pAD52PD89,
and pfimH52 into pili was confirmed by immunoelectron mi-
croscopy using anti-FimH antibodies. Consistent with the
FIG. 1. FimH52 and FimH89 are highly conserved in sequence and structure. (A) The FimH amino acid sequences of E. coli UTI89 and K.
pneumoniae TOP52 are shown. Residues known to interact with mannose (orange) and form the hydrophobic ridge (green) are fully conserved.
The purple line denotes sequence of the AD, the blue line denotes sequence of the PD, and the yellow line denotes the short linker region. Amino
acid numbers refer to the mature protein without signal sequence. (B) Structure of E. coli FimH (yellow) (from the J96 strain FimC-H complex;
PDB identification no. 1KLF) bound to mannose (red) overlaid with a threaded model of K. pneumoniae TOP52 FimH. Side chains of TOP52
amino acids that vary from the UTI89 sequence are shown as blue sticks. (Inset) Space-filling model of a view into the mannose binding pocket
(same colors described above). This shows that all residues in direct contact with the mannose moiety and those that form the hydrophobic ridge
are fully conserved between E. coli UTI89 and K. pneumoniae TOP52.
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phase switch being primarily off in these complementations,
the majority of bacteria were bald without noticeable pili.
However, similar subpopulations of bacteria existed in each
sample that were moderately piliated and immunolabeling at
the tips of pili was observed for UTI89 fimH complemented
with each construct (Fig. 3). The low level of type 1 pilus
expression explains the inability to fully complement UTI89
fimH to wild-type E. coli UTI89 MSHA titers.
TOP52 fimH was also complemented with each FimH chi-
mera and the MSHA titers for all strains were analyzed (Table
4). Wild-type UTI89 produced an MSHA titer of 1:512, while
wild-type TOP52 was hemagglutination negative. UTI89
fimH, UTI89 fimH/pBAD, TOP52 fimH, and TOP52
fimH/pBAD all lacked the ability to agglutinate guinea pig
RBCs. UTI89 fimH/pfimH89 and UTI89 fimH/pAD89PD52
both produced an MSHA titer of 1:32, while UTI89 fimH/
pAD52PD89 and UTI89 fimH/pfimH52 did not produce a
hemagglutination titer. This trend was recapitulated in the
TOP52 fimH background. While TOP52 fimH/pfimH52 and
TOP52 fimH/pAD52PD89 both lacked hemagglutination ti-
ters, TOP52 fimH/pfimH89 and TOP52 fimH/pAD89PD52
both produced MSHA titers of 1:16.
These results demonstrate that the K. pneumoniae TOP52
FimH inability to agglutinate guinea pig RBCs is specific to its
AD. The AD of E. coli UTI89 FimH is capable of agglutinating
guinea pig RBCs with the native UTI89 PD or with the PD of
K. pneumoniae TOP52. Thus, variations between the FimH
ADs of E. coli UTI89 and K. pneumoniae TOP52 are likely
responsible for their differences in function.
K. pneumoniae TOP52 FimH-dependent biofilms are inhib-
ited by heptyl mannose but not methyl mannose. K. pneu-
moniae TOP52 is able to form biofilm at room temperature
when the production of type 1 pili is induced via the E. coli
recombinase, coded for by fimX (50). Thus, we investigated
whether this biofilm was FimH dependent. Biofilms were
stained with crystal violet and quantified after 48 h of incuba-
tion. Wild-type TOP52 and TOP52/pBAD vector control did
not form biofilm, while TOP52/pfimX formed biofilm. TOP52
fimH, TOP52 fimH/pBAD, and TOP52 fimH/pfimX did
not form biofilm, suggesting that the TOP52/pfimX biofilm is
FIG. 2. The fim operon of UTI89 fimH is primarily in the phase-
off orientation. Phase assays of the fimS invertible promoter region of
the fim operon were done for E. coli UTI89, UTI89 fimH, UTI89
fimH/pBAD, UTI89 fimH/pfimH89, and UTI89 fimH/pfimH52.
UTI89 was largely phase on, while the UTI89 fimH strains were all
primarily phase off despite complementation.
FIG. 3. fimH constructs in UTI89 fimH are expressed in some bacteria and localized at the tips of pili. Immunoelectron microscopy using an
anti-FimH antibody was performed against UTI89 fimH/pfimH89 (A), UTI89 fimH/pAD89PD52 (B), UTI89 fimH/pAD52PD89 (C), and UTI89
fimH/pfimH52 (D). While the majority of bacteria did not appear to be expressing type 1 pili, piliated bacteria could be found in all four samples.
Piliated bacteria displayed FimH immmunostaining at the distal tips of pili.
TABLE 4. Adhesin domain-specific hemagglutination deficiency of
K. pneumoniae TOP52 FimH52
Strain







UTI89 fimH 2 2
UTI89 fimH/pBAD 0 0
UTI89 fimH/pfimH89 5 0
UTI89 fimH/pAD89PD52 5 0
UTI89 fimH/pAD52PD89 0 0
UTI89 fimH/pfimH52 0 0
TOP52 0 0
TOP52 fimH 0 0
TOP52 fimH/pBAD 0 0
TOP52 fimH/pfimH89 4 0
TOP52 fimH/pAD89PD52 4 0
TOP52 fimH/pAD52PD89 0 0
TOP52 fimH/pfimH52 0 0
a HA titer data are representative of three independent experiments.
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FimH dependent. Thus, although FimH52 is unable to mediate
hemagglutination, it is capable of mediating biofilm formation.
E. coli UTI89 formed a robust biofilm, while UTI89 fimH did
not. The formation of E. coli UTI89 biofilm was fully inhibited
by 100 mM methyl mannose or 1 mM heptyl mannose (Fig. 4).
In contrast, TOP52/pfimX biofilm formation was not affected
by the presence of 100 mM methyl mannose, but was fully
inhibited by 1 mM heptyl mannose.
Therefore, TOP52/pfimX forms a FimH-dependent biofilm
that is inhibited by heptyl mannose but not methyl mannose.
This phenotype is distinct from those of E. coli UTI89 FimH-
dependent biofilms, which are fully inhibited by the presence
of 100 mM methyl mannose.
E. coli UTI89 and K. pneumoniae TOP52 both require fimH
for effective persistence in the urinary tract. To analyze the
respective roles of FimH52 and FimH89 in urinary tract infec-
tion, 107 CFU of E. coli UTI89, UTI89 fimH, K. pneumoniae
TOP52 or TOP52 fimH were inoculated into the bladders of
C3H/HeN mice by transurethral catheterization. Bladders and
kidneys were harvested at various time points postinoculation,
and bacterial titers were determined. In the bladder (Fig. 5A),
E. coli UTI89 had significantly higher titers than UTI89 fimH
at 6 h (P  0.0001), 24 h (P  0.0001), and 336 h (P 
 0.0007)
postinfection. UTI89 fimH was cleared from the bladder as
time progressed. K. pneumoniae TOP52 had slightly but signif-
icantly higher titers (P 
 0.0244) than TOP52 fimH in the
bladders of mice at 6 h postinoculation. By 24 h, there was no
significant difference between TOP52 and TOP52 fimH blad-
der titers. However, by 336 h postinfection, TOP52 fimH had
significantly lower titers than wild-type TOP52 (P
 0.0012). In
the kidneys (Fig. 5B), UTI89 had significantly higher titers
than UTI89 fimH at 6 h postinfection (P  0.0001), however
the two strains had similar titers at both 24 and 336 h postin-
fection. TOP52 and TOP52 fimH had similar levels of bac-
terial burden in the kidneys at all time points tested. Thus,
FimH in K. pneumoniae TOP52 does not play a critical role
early in bladder infection as is the case with E. coli UTI89;
however, FimH is required for effective persistence in the
bladder in both strains.
FimH52 is required for K. pneumoniae TOP52 bladder inva-
sion and IBC formation. In order to further assess the role of
FimH52 in acute K. pneumoniae TOP52 cystitis, bladder inva-
sion assays were performed at 1 h postinfection with UTI89,
UTI89 fimH, TOP52, or TOP52 fimH. In these assays, lu-
minal bacteria were collected by successive bladder washes
(Fig. 5C), prior to gentamicin treatment of the bladder to kill
extracellular bacteria, as previously described (33). After 1.5 h
of incubation in gentamicin, bladders were washed and homog-
enized and cell titers were determined to reveal the intracel-
lular bacterial burden (Fig. 5D). UTI89 had 100-fold-higher
luminal bacterial counts compared to UTI89 fimH at 1 h
postinfection (P 
 0.0043). However, TOP52 and TOP52
fimH had similar levels of luminal colonization. At this 1-h
time point, UTI89 had significantly higher levels of intracellu-
lar bacteria than UTI89 fimH (P 
 0.0055), which did not
have any intracellular titers above the limit of detection (5
CFU). TOP52 also invaded into the bladder tissue and had
intracellular bacterial titers that were significantly higher than
TOP52 fimH (P 
 0.0095), which did not have titers above
the limit of detection.
To determine if the presence of FimH52 affects the ability of
TOP52 to form IBCs, we visualized and quantified IBCs by
lacZ staining of whole, mounted, fixed bladders as described
previously (33) at 6 h postinoculation of UTI89, UTI89 fimH,
TOP52, or TOP52 fimH (Fig. 5E). UTI89 formed a wide
range of IBCs with a median of 25.5 per bladder, while UTI89
fimH formed no detectable IBCs. TOP52 had a median of 2.0
IBCs per bladder, while TOP52 fimH was unable to produce
detectable IBCs (P 
 0.0009).
These data suggest that K. pneumoniae TOP52 FimH52, in
contrast to E. coli UTI89 FimH89, does not play a significant
role in early bladder colonization. However, FimH52 is re-
quired for TOP52 invasion and IBC formation in the murine
bladder, as is the case for UTI89.
fimH52 does not restore the ability of UTI89 fimH to effec-
tively infect the bladder. E. coli UTI89 relies on FimH to
successfully cause UTI in the murine model. The ability of
fimH52 to restore the ability of UTI89 fimH to bind, invade,
and infect murine bladders was investigated by using UTI89
fimH complemented with pBAD vector control, pfimH89, and
pfimH52. In 1-h gentamicin protection assays (Fig. 6A and B),
UTI89 fimH complemented with pfimH89 had significantly
higher luminal titers than the same strain complemented with
vector control (Fig. 6A, P 
 0.0001) despite the known expres-
sion deficiencies observed above. Additionally, UTI89 fimH/
pfimH89 had significantly higher 1-h luminal titers than UTI89
fimH/pfimH52, which had colonization levels similar to those
of the vector control. Examination of the intracellular popula-
tion at 1 h (Fig. 6B) revealed that the UTI89 fimH/pBAD
vector control did not have titers above the limit of detection,
whereas UTI89 fimH/pfimH89 did produce significantly
higher burdens of intracellular bacteria (P 
 0.0028). UTI89
fimH/pfimH52 was able to invade the bladder tissue, but at
significantly lower levels compared to UTI89 fimH/pfimH89
FIG. 4. Heptyl mannose, but not methyl mannose, inhibits FimH-
dependent biofilm formation of K. pneumoniae TOP52/pfimX. A 48-h
biofilm assay was used to quantify biofilms produced by E. coli UTI89
and K. pneumoniae TOP52 strains in the presence of no mannose, 1
mM methyl mannose, 100 mM methyl mannose, or 1 mM heptyl
mannose. TOP52 forms a FimH-dependent biofilm with induced ex-
pression of type 1 pili via the E. coli recombinase, fimX. This biofilm
formation is inhibited by heptyl mannose but not high concentrations
of methyl mannose. UTI89 forms robust biofilm without mannose but
is inhibited by heptyl mannose or high concentrations of methyl man-
nose. Error bars represent standard deviations.
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 0.0106). At 6 h postinoculation, UTI89 fimH/pfimH89
had significantly higher burdens of bacteria in the bladder than
both UTI89 fimH/pBAD (P 
 0.0043) and UTI89 fimH/
pfimH52 (P
 0.0032). Complementation of UTI89 fimH with
fimH from either UTI89 or TOP52 did not significantly affect
6-h kidney titers compared to those of the vector control.
The fimH52 gene was not able to restore UTI89 fimH to
levels above that of the vector control, while complementation
with fimH89 yielded higher bacterial burdens at 1 and 6 h. This
suggests a potential defect in the function of FimH52 in the
bladder compared to FimH89.
DISCUSSION
FimH of the K. pneumoniae strain TOP52 (FimH52) has an
amino acid sequence highly homologous to the sequence en-
FIG. 5. FimH of K. pneumoniae TOP52 is required for invasion, IBC formation, and persistence but not colonization in the murine model of
UTI. Female C3H/HeN mice were inoculated with 107 E. coli UTI89 (Œ), UTI89 fimH (‚), K. pneumoniae TOP52 (F), or TOP52 fimH (E)
by transurethral inoculation. For organ titers, bladders (A) and kidneys (B) were harvested at various time points postinfection and CFU were
calculated. Titer data are combined from three independent experiments. For ex vivo gentamicin protection assays, bladders were harvested at 1 h
postinfection and luminal (C) and intracellular (D) populations of bacteria were quantified. IBCs were quantified (E) after visualization by LacZ
staining at 6 h postinoculation. Short bars represent geometric means of each group, and horizontal dotted lines represent limits of detection.
Significant P values, as calculated using the Mann-Whitney U test, are displayed.
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coded by dozens of fimH genes that have been sequenced from
E. coli (34, 54, 56). The residues that form the mannose bind-
ing pocket (Asn46, Asp47, Asp54, Gln133, Asn135, and
Asp140) and hydrophobic ridge (Phe1, Ile13, Try48, Ile52,
Tyr137, and Phe142) are completely identical between FimH52
and all known FimH adhesins of E. coli. Despite this identity,
FimH52 has a receptor specificity unique from that of UPEC
FimH. FimH52 is unable to mediate agglutination of guinea pig
erythrocytes, whereas all known UPEC FimH adhesins are
defined by their ability to mediate MSHA. Different E. coli
FimH variants have been classified as high-affinity monoman-
nose binders or lower-affinity trimannose binders (45, 54).
However, both trimannose and monomannose variants display
MSHA of guinea pig erythrocytes.
E. coli FimH recognizes mannose and has been shown to
be able to interact with Man1, 3Man1, 4GlcNAc1,
4GlcNAc in an extended binding site (61). These additional
interactions between FimH and extended oligomannose
moieties are mimicked by butyl -D-mannose (61). Extended
alkyl--mannosides have higher affinities for E. coli FimH
compared to methyl--D-mannopyranoside (methyl man-
nose), with heptyl -D-mannopyranoside (heptyl mannose)
having the lowest dissociation constant (Kd) of 5 nM (5). K.
pneumoniae FimH-dependent biofilms could only be inhib-
ited by heptyl mannose and not methyl mannose, arguing
that K. pneumoniae FimH requires additional contacts of the
alkyl chain outside of the mannose binding pocket.
FimH52 differs at 17 positions from E. coli FimH and was
threaded onto the three-dimensional structure of E. coli FimH.
In the DE loop, adjacent to the hydrophobic ridge, Val94 and
Asn96 of E. coli UTI89 FimH (FimH89) are changed to Ile and
Asp, respectively, in FimH52. In the G strand, immediately C
terminal to key residues in the hydrophobic ridge, Val145 in
FimH89 is changed to Ile in FimH52. Combined, these differ-
ences may alter the structural stability of the hydrophobic ridge
of FimH52 through changes in hydrophobic and hydrogen bond
contacts. Thus, although FimH52 is unable to bind methyl
mannose, these amino acid changes may facilitate interactions
with longer oligomannose substrates (61).
The inability of FimH52 to mediate hemagglutination may
be due to amino acid changes in proximity to the mannose
binding pocket. Gln133 and Asp140 E. coli FimH residues
are required for HA titers and mannose binding (29). Two
differences in K. pneumoniae TOP52 primary sequence exist
in residues adjacent to these mannose-binding residues at
positions 132 and 141. Data from the threaded model sug-
gest that at least two hydrogen bonds are lost in FimH52 with
the combined differences in residues 132 and 141, which may
have a destabilizing effect on interactions at the mannose
site around the Asp140 and Gln133 mannose-binding resi-
FIG. 6. Complementation of UTI89 fimH with pfimH89 but not
pfimH52 leads to increased bacterial burden in the murine model of
UTI. Female C3H/HeN mice were inoculated with 107 cells of the
UTI89 fimH/pBAD vector control, UTI89 fimH/pfimH89, or UTI89
fimH/pfimH52 by transurethral inoculation. Ex vivo gentamicin pro-
tection assays were performed in which bladders were harvested at 1 h
postinfection and luminal (A) and intracellular (B) populations of
bacteria were quantified. For organ titers, bladders (C) and kidneys
(D) were harvested at 6 h postinfection and CFU were enumerated.
Short bars represent geometric means of each group, and horizontal
dotted lines represent limits of detection. Significant P values, as cal-
culated using the Mann-Whitney U test, are displayed.
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dues. Sequence variation in regions of FimH not in close
proximity to the mannose binding pocket may also signifi-
cantly affect FimH function (56, 57).
Studies have suggested that fimbrial shafts can influence
binding specificities of type 1 pili (16, 38). These effects do
not account for the binding specificity differences observed
for FimH52. FimH52 assembled into E. coli UTI89 type 1 pili
was also hemagglutination negative, and FimH89 assembled
into K. pneumoniae TOP52 type 1 pili produced an MSHA
titer. Thus, the major functional disparities between E. coli
and K. pneumoniae type 1 pili were specific to the AD of
FimH, not the strain background or fimbrial shaft. However,
fimbrial shafts may influence FimH binding in more subtle
ways that could have been missed in this study due to the
lower expression of type 1 pili in fimH-knockout back-
grounds.
The binding specificity differences observed for FimH52
result in dramatic functional differences seen in K. pneu-
moniae UTI pathogenesis compared to E. coli UTI patho-
genesis. Although K. pneumoniae TOP52 requires FimH for
invasion and IBC formation in the murine bladder, FimH is
not essential for early colonization. TOP52 and TOP52
fimH have similar 1-h luminal bladder titers, 24-h whole-
bladder titers, and only modest titer differences at 6 h
postinfection. The small but significant differences at 6 h
likely represent the intracellular population of bacteria in
IBCs within TOP52-infected bladders that are absent in
TOP52 fimH-infected bladders. K. pneumoniae may use a
different, non-type 1 pilus adhesin for initial binding to the
bladder surface that E. coli lacks. This would explain why
TOP52 fimH had higher 1-h luminal titers and 6-h whole-
bladder titers compared to UTI89 fimH. K. pneumoniae
contains a gene that encodes type 3 pili; however, these pili
have not been implicated in binding to the bladder surface
and are thought to mediate attachment to the basolateral
surface of tracheal epithelial cells and basement membrane
components (60). In addition to type 1 and type 3 pili, K.
pneumoniae genes encode at least two other non-pilus ad-
hesins. The CF29K and KPF-28 adhesins may play impor-
tant roles in mediating attachment within the mammalian
intestine, but their role in UTI has not been investigated
(9, 12).
For many years, the glycoprotein uroplakin Ia has been
considered the main receptor mediating FimH-dependent ad-
hesion in the bladder (42, 63). Recently, it has been shown that
host cell integrins also can mediate type 1 pilus-dependent
invasion of urothelial cells (17). We currently do not know if K.
pneumoniae FimH52 is capable of binding these receptors. It is
possible that FimH52 may only be capable of binding integrin
receptors (and not uroplakin Ia) for invasion of urothelial cells
but not necessarily mediating significant adhesion to the uro-
plakin-coated bladder surface. Alternatively, K. pneumoniae
FimH may have evolved for binding to a receptor in a different
environment from the bladder.
This work focused on a single uropathogenic isolate of K.
pneumoniae, and it is important to extend this work to other
strains. The sequence of TOP52 FimH was almost identical to
those of other sequenced K. pneumoniae FimH proteins and
thus may be representative. The inability of K. pneumoniae
TOP52 to agglutinate guinea pig RBCs is not an isolated find-
ing. The ATCC 700721 strain also lacks an MSHA titer. The
first studies of fimbriae and adhesive properties of 154 K.
pneumoniae isolates found that 57.6% of strains produced little
or no MSHA titer (13). Many researchers considered this to be
due to poor type 1 expression in K. pneumoniae. However, K.
pneumoniae TOP52 remained hemagglutination negative when
expression of type 1 pili was increased by deletion of fimK or
overexpression of fimX. Additionally, expression of E. coli type
1 pili at similar levels to TOP52 type 1 pili resulted in a positive
MSHA.
This study suggests that limited sequence variation be-
tween the FimH of E. coli and K. pneumoniae results in
differences in function and ability to colonize the urinary
tract. Despite its poor adhesive properties in the urinary
tract, FimH of K. pneumoniae remains an important viru-
lence factor. It enables K. pneumoniae to progress through
an IBC pathway during UTI and ultimately persist in the
host. K. pneumoniae FimH likely requires ligand-receptor
contacts outside of the mannose binding pocket for efficient
binding. Further insight into these structural determinants
will aid in our understanding of the altered host-pathogen
interactions of K. pneumoniae UTI.
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